Ralf C. Bargou

Comprehensive Cancer Center Mainfranken — Germany

Medicine · Health Sciences

66h-index19.3kcitations310works8.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(102), CAR-T cell therapy research(80), Monoclonal and Polyclonal Antibodies Research(46), Acute Lymphoblastic Leukemia research(39), Cancer-related Molecular Pathways(33)

Publications310 total

Priority European strategies for sustainable access to high-quality genetic counselling in cancer: A Delphi study
European Journal of Human Genetics·2026Open Access
Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Experimental Hematology and Oncology·2025Open Access
YBX1 modulates humoral immunity through post-transcriptional regulation in B cells
Frontiers in Immunology·2025· 1 citedOpen Access
174TiP RATIONALE: Randomized comparison of treatment guided by comprehensive genome and transcriptome analysis versus standard of care in patients with advanced rare cancers
Annals of Oncology·2025
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer
JCO Precision Oncology·2025· 1 citedOpen Access
CAR-T-Zell-Therapie bei der akuten lymphoblastischen Leukämie
Die Innere Medizin·2025
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Nature·2025· 2 citedOpen Access
Correction: Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic
Journal of Cancer Research and Clinical Oncology·2025Open Access
Additional file 1 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
Additional file 13 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
Additional file 8 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
Additional file 5 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
Additional file 10 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
Additional file 12 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
Additional file 11 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
Additional file 7 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
Additional file 4 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
Additional file 5 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
Additional file 2 of Efficacy of melflufen in multiple myeloma with mutated or deleted TP53
Figshare·2025Open Access
page 1 of 16Next →

Frequent Co-authors

Peter Kufer(15), Patrick A. Baeuerle(14), Kurt Bommert(12), Gerhard Zugmaier(11), Hermann Einsele(11), Bernd Dörken(11), Manik Chatterjee(10), Dirk Nagorsen(9), Max S. Topp(8), Nicola Gökbuget(8), Andreas Viardot(8), Svenja Neumann(7), Monika Brüggemann(7), Markus Y. Mapara(7), Thorsten Stühmer(7), Matthias Klinger(6), Christian Brandl(6), Gert Riethmüller(6), Matthias Stelljes(6), Maria-Elisabeth Goebeler(6)